Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions, except per share amounts) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 7,803 | 7,082 | 14,763 | 13,749 |
| Costs and expenses: | ||||
| Cost of goods sold | 1,579 | 1,501 | 3,023 | 3,041 |
| Research and development expenses | 1,764 | 1,491 | 3,136 | 2,870 |
| Acquired in-process research and development expenses | 11,183 | 61 | 11,290 | 315 |
| In-process research and development impairments | 1,750 | 190 | 1,750 | 190 |
| Selling, general and administrative expenses | 1,921 | 1,365 | 3,372 | 2,623 |
| Total costs and expenses | 18,197 | 4,608 | 22,571 | 9,038 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's R&D?
- Gilead Sciences (GILD) reported R&D of $1.76B in Q2 2026.
- How has Gilead Sciences's R&D changed year-over-year?
- Gilead Sciences's R&D increased by 18.3% year-over-year, from $1.49B to $1.76B.
- What is the long-term trend for Gilead Sciences's R&D?
- Over 4 years (2021 to 2025), Gilead Sciences's R&D has grown at a 5.9% compound annual growth rate (CAGR), from $4.61B to $5.8B.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Gilead Sciences's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude